drugset / Trial / NCT02865720

Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)

NCT02865720

Phase 3 Completed 8 enrolled Shire
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if an investigational treatment is safe and well tolerated when administered by intravenous (IV) infusion in Japanese subjects with HAE.

Timeline

Start
2016-09-08
Primary completion
2017-06-23
Completion
2017-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject CINRYZE Protein / enzyme biologic 500 iu Intravenous
Subject CINRYZE Protein / enzyme biologic 1000 iu Intravenous

Indications